GSK blows Jemperli marching brass against Keytruda with expanded FDA nod in endometrial cancer

Merely a month into an FDA approval for a broad first-line endometrial cancer population, Merck’s Keytruda has some company.

On Thursday, the FDA expanded the endometrial cancer use for GSK’s Jemperli, used in combination with chemotherapy, to include patients with mismatch repair proficient (pMMR) or microsatellite-stable (MSS) tumors.